LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $21,118.25 today based on a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...